Entering the pharmaceutical and laboratory markets of the UAE, Saudi Arabia and Egypt means working with three national regulators, each with its own pathways, systems and expectations. Companies often look for a pharmaceutical regulatory consultant in Saudi Arabia or the UAE at the start of that process, and a clear picture of the landscape makes that conversation far more productive. This article is an overview of how registration is organised in the three markets. It is not regulatory advice: requirements change, and every product should be confirmed with the relevant authority.
Who regulates what
United Arab Emirates. Medicines and medical devices are regulated at federal level. Emirate-level health authorities license healthcare facilities and professionals within their emirates.
Saudi Arabia. The Saudi Food and Drug Authority (SFDA) regulates medicines, medical devices, cosmetics and food. Submissions are made through the SFDA's electronic systems.
Egypt. The Egyptian Drug Authority (EDA) is the national regulator for medicines and related products.
Across the GCC there is also a centralised procedure coordinated at regional level, although national registration remains the usual route.
Which products need registration
Registration requirements depend on what the product is and how it is intended to be used.
| Product type | Typical regulatory route |
|---|---|
| Medicines, including generics and biologics | Marketing authorisation from the national regulator |
| Medical devices | Device registration or marketing authorisation, classified by risk |
| In-vitro diagnostic reagents and instruments | Regulated as IVD medical devices in most frameworks |
| Research-use-only laboratory products | Usually not registered as devices; import rules may still apply |
| Laboratory equipment for QC and research | Usually not a regulated medical product unless intended for diagnosis |
The intended use stated by the manufacturer is decisive. The same instrument can be an unregulated laboratory product in one configuration and an IVD device in another. Getting the classification right early avoids registering products that do not need it, or importing products that should have been registered.
Two examples show how intended use shapes the answer. Liquid-handling instruments used in pharmaceutical QC laboratories, such as those on our liquid handling and bioprocess equipment page, are generally laboratory products rather than medical devices. Reagents used for pharmaceutical quality control, such as those for endotoxin testing of injectable products, test the medicine rather than the patient, so they are not normally treated as diagnostics. The same logic applies to culture media and enzymes used in QC.
The medicine dossier
Most regulators in the region accept the Common Technical Document (CTD) structure developed by ICH:
- Module 1: regional administrative information, including application forms, labelling and product information in the required languages.
- Module 2: summaries of quality, non-clinical and clinical data.
- Module 3: quality, covering manufacture, controls and stability.
- Module 4: non-clinical study reports.
- Module 5: clinical study reports.
Region-specific requirements commonly include evidence of GMP compliance of the manufacturing site, a certificate of pharmaceutical product or equivalent evidence of approval in the country of origin or a reference country, and stability data under conditions relevant to the region's hot climate. Arabic labelling or product information is generally required for products sold in the market.
Reliance and abridged pathways
Regulators increasingly rely on decisions made by reference authorities to speed up review. Where a product is already approved by a recognised agency, abridged or verification pathways may apply. These pathways reduce review effort but do not remove the need for a complete, well-prepared dossier and local requirements such as labelling and pricing.
Local presence and responsibilities
Foreign manufacturers usually need a local representative, agent or marketing authorisation holder in each country, who carries regulatory responsibilities such as submissions, safety reporting and communication with the authority. Choosing that partner is as important as preparing the dossier.
Facilities and inspections
Registration of a medicine depends on the GMP status of its manufacturing site. Regulators may accept evidence from recognised inspectorates or conduct their own inspections. For companies building or upgrading facilities in the region, planning the facility, its quality system and its documentation with inspection in mind is far easier than correcting gaps afterwards.
Pricing, safety and post-approval changes
Approval is not the end of the process. Several markets regulate the price of medicines as part of, or alongside, registration. Marketing authorisation holders must report adverse events and maintain pharmacovigilance systems, and changes to the product, its manufacture or its labelling after approval are filed as variations. Planning for these ongoing obligations from the start avoids surprises after launch.
When to bring in a pharmaceutical regulatory consultant in Saudi Arabia
Specialist support is most valuable in a few situations:
- First entry into the market, when local systems, formats and expectations are unfamiliar.
- Parallel registration in several countries, where dossiers can be planned together and duplicated effort avoided.
- Novel or complex products, such as biologics, combination products or new diagnostic technologies.
- Classification questions, especially for laboratory products that may or may not be medical devices.
- Facility projects, where the laboratory or plant and its regulatory approval must be planned together.
- Limited internal resources, when a small regulatory team cannot cover several markets at once.
A good consultant helps you map each product to its pathway, identify gaps in your documentation, plan submissions in a sensible order, and communicate with the authority. They cannot guarantee outcomes or timelines, which remain with the regulator.
A practical starting checklist
- List products, their intended use and target countries.
- Confirm the regulatory classification of each product in each country.
- Check what evidence you already hold: approvals, GMP certificates, stability data, labelling.
- Identify your local representative or marketing authorisation holder.
- Plan the submission sequence and the resources needed.
- Check each regulator's current published guidance before you submit, since requirements, forms and electronic systems change over time.
How Arab Lab can help
Arab Lab's Pharmaceutical Consultant line combines regulatory consulting with turnkey project services for companies in the UAE, Saudi Arabia and Egypt, and its turnkey laboratory projects line delivers facilities built with compliance in mind. Scope is agreed for each engagement. Send your products, target markets and timeline through the contact page to discuss your situation.